A UK drug discovery company has announced the appointment of a chief scientific officer (CSO).
C4X Discovery (AIM: C4XD) has promoted Nick Ray (pictured) to the role. He has been credited with playing a key part in the company’s growth since joining the firm in 2016.
A medicinal chemist by training, Dr Ray is currently the company’s senior vice president (SVP) for drug discovery, leading the medicinal chemistry, structural analysis and computational chemistry teams.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze